Neoadjuvant epirubicin/docetaxel (ET) concomitant chemotherapy for primary breast cancer with tumor diameter >=3.1 cm: results of the Kyushu ET therapy phase II trial.Reiki Nishimura, Kazuo Tamura, Shinsuke Hara et al.|PubMed|2012Cited by 3
[Docetaxel in combination with epirubicin as the first-line chemotherapy for advanced and recurrent breast cancer: a multicenter phase II study].Keisei Anan, Kazuo Tamura, Maki Tanaka et al.|PubMed|2012Cited by 0